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ABSTRACT

Background: Rheumatoid Arthritis (RA) is a chronic disease associated with poor quality of life
of patients, lifelong dependency on medications and long-term disease suffering which leads to
both physical and financial disability in terms of cost. RA flare and complications lead to
hospitalization and demand in-patient care and these costs impose a significant burden on the
patients especially those from a poor socioeconomic background in a developing society like India
where the country reserves only 1.4% of the income for healthcare.
Objective: The objective of this study is to find the cost of illness associated with hospitalized
patients suffering from Rheumatoid Arthritis and understand the prescription pattern of drugs for
the same.
Methodology: A retrospective research study was conducted on in-patients diagnosed with
Rheumatoid Arthritis in the Medicine department, in a tertiary care hospital setting. The patient
files were obtained from the In-patient Medical Records Department after obtaining proper ethical
approval from the hospital Institutional Ethics Committee. The finance data was collected from
the Finance Department in the hospital. Data was collected in case record forms designed for the
study and entered SPSS for analysis.
Results: The most commonly prescribed Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
was Methotrexate prescribed for 202 patients (62%) followed closely by Hydroxychloroquine
prescribed to 194 patients (59.6%). They were also the most commonly prescribed drugs as a
combination therapy at 45.9%. The total median cost for single admission was found to be INR
12, 247.
Conclusion: INR 12, 247 is a very high amount in a developing country such as India. First year
of symptoms is where most of the patients come to hospital to get RA diagnosis and is also the
peak time to start effective treatment regimen, disease education and awareness to ensure that
disease progression can be prevented by reinforcing the importance of medication adherence
among patients. This is a white space role that can be taken up by health care professionals.
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INTRODUCTION
1.

Introduction

Rheumatic Arthritis (RA) is a chronic systemic disease that affects the joints, connective tissues,
muscle, tendons, and fibrous tissue. If left untreated, RA can lead to pain, disability, loss of
function, reduced quality of life (QoL) and premature mortality. Within 10 years of onset, at least
50% of patients suffering from RA in developed countries are unable to hold down a full-time
job (WHO-Chronic Rheumatic conditions, 2016).
Approximately 1% of adult population of the world and 0.7% population in India is affected with
RA (Kevin, 2004). The disease is of unknown origin, but it is immunologically medicated. RA is
2-3 time more common in women as compared to men, but symptoms in men tend to be more
severe. Occurrence of RA is predominantly in women with the peak incidence occurring in
women between the ages of 50-60 years old.
Rheumatoid Arthritis is characterized by morning stiffness as well as swelling of symmetrical
joints in hands, knees and legs (feet). It can lead to permanent joint damage if left uncontrolled
without proper treatment. The treatment for RA includes both non-pharmacological and
pharmacological approach. It focus on pain reduction, alleviating swelling, preventing joint
deformity and improving QoL of patients. Physical therapy, exercise, devices for assistance like
walking canes, changes in lifestyle especially reducing stress, weight reduction and healthy
eating are some of the non-pharmacological treatments suggested for RA patients.
Pharmacological treatment includes five main classes of drugs: analgesics, non-steroidal antiinflammatories (NSAIDs), glucocorticoids, non-biologic and biologic disease-modifying antirheumatic

drugs

(DMARDs).

The

American

College

of

Rheumatology

treatment

recommendations and guidelines advice physicians to start with biologics if the RA patients have
less than optimal response or cannot tolerate DMARDs. Methotrexate, sulfasalazine, leflunomide
and hydroxychloroquine are the commonly used DMARDs for the treatment of RA (Kumar and
Banik, 2013).
5

A higher prevalence of RA in females has been reported in India compared to developed
countries and this could probably be linked to cultural and ethnic diversity, mainly those
surrounding occupation and living conditions. A study found that female predominance had
consisted mainly of housewives and only few (8.69%) were working. This may not affect the
source of family funding but may definitely impose socio economic burden on the family
(Gawde, 2013).
The economic burden for Rheumatoid Arthritis is of significance for both the patients as well as
healthcare services. Even though musculoskeletal diseases do not directly impact mortality, they
play a huge role society burden in terms of long-term disability, cost and morbidity. The
quantification of burden in terms of cost with such musculoskeletal diseases like RA can be used
as proxy models to estimate the cost burden it places on the patients, payers or healthcare
services of a country.
The cost can be quantified in terms of direct, indirect and intangible cost. Direct costs include
cost of medication, hospitalization, diagnostic tests. Indirect costs are due to loss of productivity
including sick leaves, early retirement and absence from work due to illness. Intangible costs are
defined as the pain and suffering of the patient due to the disease which may include reduction in
movement, psychological and social impact on the on QOL not only of the patient but also of the
family (Kvien, 2004).
Rheumatoid arthritis patients have a high level of disability which in turn have a negative impact
on psychological and social function of the patient; the consequences of which include mental
distress, depression and fatigue (Smedstad et al., 1996). Pain and disability are the two variables
most consistently related to mental distress. High levels of disability with a consequent decreased
ability to cope are commonly associated with depression, even in the early stages of the illness
(Smedstad et al., 1997).
Cost of Illness studies provide informative data to emphasize the scale and nature of the disease
as a health problem and raise awareness about the burden of the disease to the patients. Direct
costs are those costs where actual payment in monetary terms is paid such as medical costs,
6

hospitalization cost and treatment costs for the disease. This study focuses on Cost of Illness
from direct cost to patient perspective.
Economic analysis on the Cost of Illness for RA studies conducted in the west cannot be
extrapolated to India due to difference in government and healthcare systems between the
countries. Very few studies have been conducted to analyze the cost burden of Rheumatoid
Arthritis in Indian setting. With regards to that, our study aims to fill the gap by providing a
study with the sample of RA patients from South Indian tertiary care hospital.
The current Indian healthcare sector mainly depends on out-of-pocket costs and insurance plays
a very small role in controlling towards the healthcare industry. Due to this, patients bear a large
burden of the cost. Big Pharma, government politics as well as payers should take into
consideration both the direct and indirect costs of chronic diseases such as Rheumatoid Arthritis
while framing the health politics as the first step towards this herculean problem.
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NEED FOR THE STUDY
2.

Need for the Study

The disease affects 1.3 million patients in the United States alone (Helmick et al., 2008) which
increased to an estimated 1.5 million patients 2007 (Myasoedova et al., 2010). The mortality rate
is around 70% higher in patients suffering from RA when compared to general public and the
survival gap between these groups appears to be widening with each year (Mikuls, 2010).
Many individuals report work absenteeism and the loss in productivity associated with the
disease can be considered substantial because of its long progressive and chronic symptoms.
Among those employees who did miss work, there were substantially more leaves taken by
patients diagnosed with Rheumatoid Arthritis. An estimated 20-70% of patients who were
working during the time of diagnosis with RA reported disability 7-10 years down the line
(Burton et al., 2006). Another study revealed that quarter to half of the patients suffering from
Rheumatoid Arthritis reported they were unable to work within ten to twenty years of after
diagnosis (Mikuls, 2010)
Nearly half (43.6%) of the patients with RA faced challenges paying medical and medicine bills
after inspite of having support from payers according to a study in US. An average of 9% percent
reported great burden from RA and this financial burden was significantly higher for patients
more than sixty five years old (11.8%) compared to those patients who were younger than sixty
five years (5.3%) (Wolfe and Michaud, 2009)
However, all these statistics surrounding the financial burden of Rheumatoid Arthritis is reported
from research studies conducted in the West. Extrapolating these studies to Indian setting is not
ideal as the Indian healthcare system has not fully incorporated insurance schemes and most of
the medical bills are paid through out of pocket costs. This study focuses on filling the gap of
discussing the pharmacoeconomics of Rheumatoid Arthritis at an Indian setting and estimating
the cost of illness of the disease.
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AIM AND OBJECTIVES
3.

Aim and Objectives
To evaluate prescription pattern in patients with Rheumatoid Arthritis.
To estimate cost of illness in the management of Rheumatoid Arthritis.
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REVIEW OF LITERATURE
4.

Review of Literature

4.1

Definition

Rheumatic Arthritis (RA) is a chronic systemic disease that affects the joints, connective tissues,
muscle, tendons, and fibrous tissue. If left untreated, RA can lead to pain, disability, loss of
function, reduced quality of life (QoL) and premature mortality (WHO-Chronic Rheumatic
conditions, 2016).
4.2

Etiology

The exact cause of RA is unknown. Studies have revealed that genetic, environmental, hormonal,
immunologic and infectious factors are known to contribute to RA. Advanced age, diabetes,
obesity, osteoporosis and regular smoking have been positively linked to RA. Socio-economic
factors such as living in poor conditions without health insurance were also positively associated
with RA. The exact impact of these factors has not been quantified but hypothesis suggests that
modification of these factors may help reduce the risk of developing RA (Xu and Lin, 2017).
Genetic factors may increase the risk of developing RA by up to 50%. Patients who carry a
shared epitope of the human leukocyte antigen (HLA)-DR4 cluster are at a higher risk of RA
(Barton and Worthington, 2009).
The gender prevalence in Rheumatoid Arthritis indicates that sex hormones may also be a part
of the etiology of the disease. RA gets ameliorated during pregnancy as well as recurrence cases
in early postpartum period and reduced incidence in women who are on oral contraceptives
backup this line of thought. Hyperprolactinemia is a risk factor for RA (Barrett et al., 1999).
Smoking, use of moist snuff, and risk of chronic inflammatory
d not increase the risk of chronic inflammatory
diseases such as RA and found that the non-nicotinic components of the cigarette smoke are the
ones which have a greater impact on the etiology of the disease than nicotine itself (Carlens et
al., 2010).
13

Immunological factors in the body have demonstrated lasting connections in the initiation,
maintenance and propagation of the autoimmune processes that result into the etiology of RA. T
cells, B cells and antigen presenting cells such as macrophages and dendritic cells as well as
various cytokines are responsible for the events of pathological significance in RA: synovial
proliferation and subsequent joint destruction. The exact mechanism of this process is complex.
The T1 helper CD4 cells which produce IL2 and interferon gamma activated macrophages and
synovial fibroblasts. Those in turn produce TNF-

and IL-1. B cells are important in the

pathologic process and may serve as antigen-presenting cells. B cells also produce numerous
autoantibodies (example RF and ACPA) and secrete cytokines. The autoimmune response leads
to the formation of immune complexes that activate the inflammatory process to a very high
degree than normal levels. This theory is supported by the much worse prognosis of RA among
patients with positive RF results (Carlens et al., 2010).
Numerous studies have shown the clinical association of microbial infection with RA. Infection
is often detected in early RA and can precede the occurrence of clinical arthritis. These
observations suggest that infection contributes to the initiation and exaggeration of RA, arguing
against the theory that the RA-associated infection is simply a sequela of immunosuppressive
treatments. The pathogenic role of infection in RA is also suggested by studies using arthritis
animal models. Infectious agents that have been suggested as potential causes for Rheumatoid
Arthritis including Mycoplasma organisms, Epstein-Barr virus (EBV) as well as rubella virus.
The link between RA and infection is supported by evidence such as occasional flu like
symptoms before the start of arthritis or the presence of bacterial products including bacterial

Among the RA associated microbes, P. gingivalis has emerged as a significant contributor to RA
etiology. It contains enzyme peptidyl arginine deiminase (PAD) which is essential for the
generation of citrullinated autoantigens. Human studies have shown the association of P.
gingivalis infection with RA patients and individuals at high risk for RA (Li et al., 2013).
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4.3

Morbidity and Mortality in Rheumatoid Arthritis

Mortality hazards in patients with Rheumatoid Arthritis are 60-70% compared with those in the
general population (Mikuls, 2010). Rheumatoid Arthritis was estimated to affect 1.3 million
adults in the U.S (Helmick et al., 2008) which increased to an estimated 1.5 million adults by the
year 2007 (Myasoedova et al., 2010).
Prevalence of RA 0.34% in India is several folds less than the elusive 1% that has been
considered as reference for several years. An approximately 5 million patients are estimated to
be suffering from RA and the facing the mortality and morbidity hazards associated with RA
(Chopra A, 2018).
4.4

Management of Rheumatoid Arthritis

The American College of Rheumatology (ACR) developed algorithms and recommendations for
biologic and non-biologic DMARDs for Rheumatoid Arthritis patients in 2008 which was
updated in 2015 (Singh et al., 2015)
The management and treatment goal in Rheumatoid Arthritis focuses on disease control and
slowing down the rate of joint damage while reducing pain, stiffness, inflammation and RA
related complications. The optimal care for RA patients consists of an integrated approach which
includes both pharmacologic and non-pharmacologic treatment approaches. Non-pharmacologic
treatments like exercise, diet, counselling, stress reduction, physical therapy, massage and
surgery are advised by patients to RA patients. Family support and active participation of patient
and their family in the implementation of treatment program ensures compliance and explaining
the importance of each therapy and treatment to the patient ensures adherence to treatment.
Pharmacologic therapies for RA include nonbiologic and biologic DMARDs as well as
adjunctive therapy such as NSAIDs, corticosteroids and analgesics. Non-biologic DMARDs
include the following: hydroxychloroquine (HCQ), sulphasalazine (SSZ), azathioprine (AZA),
methotrexate (MTX), leflunomide, cyclosporine, gold salts, D-penicillamine and minocycline.
DMARDs are the most important drugs in the successful treatment for RA represent the most
important measure in the successful treatment of RA. They are known to prevent disease
15

progression and thus assist in subsequent prevention of joint destruction and loss of function. A
successful DMARDs regimen would eliminate the need for other drugs such as analgesics and
anti-inflammatory. However, until the full action of DMARDs takes place, analgesics and antiinflammatory drugs may be needed to reduce pain and swelling.
Early treatment of RA (within few months of onset) with DMARDs will not only retard the RA
progression more efficiently than a later treatment but it may also induce more remissions
(Verstappen et al., 2005). Early DMARDs therapy within less than six months from onset of
symptoms is now considered as the standard of care (Singh et al., 2012).
DMARDs combination therapy is prescribed to patients who partly or completely fail to respond
to monotherapy regimen. In patients with early, active Rheumatoid Arthritis, combination
DMARD with downward dose titration or an intensive triple therapy is considered more costeffective than DMARD monotherapy (Tosh et al., 2011). Among the combination therapy,
several have proved successful and most including MTX example MTX+SSZ+HCQ or MTX+
Leflunomide or MTX + Biologic DMARDs.
Agency for Healthcare Research and Quality (AHRQ) has advised the following
recommendations with medium level of confidence:
Patients with early RA (less than 3 years) who have not taken methotrexate previously,
starting a monotherapy with MTX can control RA symptoms as well as monotherapy with
adalimumab or etanercept.
Combination of a biologic agent and MTX would bring better RA symptom relief instead of
using either drug alone.
For early stage RA patients, combination of sulphasalazine and MTX does not work better
than monotherapy with either agent (Donahue et al., 2012).
Biologic agents are found to be more effective than non-biologic treatments for RA patients
especially the physical function in RA. Rituximab and Etanercept were found to be most
effective treatments for RA patients who had never taken antirheumatic drugs and also in those
who had shown an inadequate response to the drugs.
16

4.5

Economic Burden of Rheumatoid Arthritis
Table 1: Pharmacoeconomic Studies on Rheumatoid Arthritis
Title of Study

Author
& Year

Study Design

Conclusion

Cost effective analysis
of disease modifying
anti-rheumatic drugs in
rheumatoid arthritis

Ashit
Syngle,
2017

Prospective, observational
study in a sample of 98 patients
followed over 3 months to
calculate the average monthly
direct cost and average costeffectiveness were calculated.

The direct medical cost of
treatment of RA per month
is 997.05 rupees. The
average cost-effectiveness
ratio of combination of
synthetic DMARDs was
1533.92 rupees.
(Syngle et al., 2017)

Cost of Illness of
rheumatoid arthritis in
South India

V Alex,
2015

Prospective observational study
was conducted over 8 months
in 200 patients to calculate the
cost of illness of RA in south
Indian patient population.

The direct cost for the
current treatment for RA
was 1929.99/month. Cost
of medicine was INR
737.49. Methotrexate was
most prescribed and
contributed to 5% of
medicine cost whereas
sulphasalazine contributed
to 25.67% of the drug cost.
(Alex et al., 2015)

Drug Utilization
pattern and Cost
Analysis in 3
Rheumatoid Arthritis
Patients 4 A Cross
sectional study in
Tertiary Care Hospital,
5 Mumbai

S.R.
Gawde,
2013

Cross-sectional study of two
months in 100 patients with RA
to calculate the average cost of
treatment and to analyze the
prescription pattern.

Average total cost per
prescription was found to
be 763.39rs, while average
hospital and out of pocket
expense were 281.12rs
respectively. 67% of the
patients were on a
combination of two
DMARDs frequently
methotrexate and HCQs.
(Gawde, 2013)
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Treatment and
monitoring costs in
rheumatoid arthritis:
Preliminary results
from an Indian setting

A systematic review of
the effectiveness of
adalimumab,
etanercept and
infliximab for the
treatment of
rheumatoid arthritis in
adults and an economic
evaluation of their
cost-effectiveness.
Impact of Switching
from an Initial Tumor
Necrosis Factor
Inhibitor on Health
Care Resource
Utilization and Costs
Among Patients With
Rheumatoid Arthritis

Tiwari,
2007

Prospective, observational
study in a sample of 96 patients
followed over 4 months to
calculate the average monthly
direct and indirect cost as well
as the cost of side effects in
patients suffering from RA.

Chen YF, Systematic review of
2006
Electronic databases searched
up to 2005. Reviews of
literature cost-effectiveness
were included as well as
industry data. BRAM model
was developed to produce
ICER and meta-analysis was
conducted.
Baser,
2015

Prospective observational study
where healthcare claims data
were obtained from a database
for confirmed RA diagnosis
who initiated anti-TNF
treatment and switched to
another biologic. Healthcare
costs and utilization during the
first 12 months.

The total average direct
cost for drug treatment was
Rs.999±76 per month. The
average monthly direct
cost and indirect cost of
RA was Rs. 623±31 and
Rs.368±62 respectively
and that for side effect
management in was Rs. 57
per patient. (Tiwari,
Sukhpreet and Agarwal,
2007)
TNF inhibitors are most
cost-effective when used
as last active
therapy. Etanercept is the
TNF inhibitor of choice.
The combination of a TNF
inhibitor with methotrexate
was more effective than
methotrexate alone in early
RA. (Chen et al., 2006)
73.3% switched to another
anti-TNF,26.7% switched
to a non-TNF. Patients
who switched to second
anti-TNFs versus a nonTNF incurred lower RArelated costs ($20,938.9 vs
$22,645.2) 1-year post
switch. These differences
were driven by increased
physician office visit costs
among the non-TNF group
(Baser et al., 2015)
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Cost-effectiveness of
combination diseasemodifying
antirheumatics vs.
tumour necrosis factor
inhibitors I in
active rheumatoid
arthritis: TACIT trial.

Patel,
2019

Tofacitinib in the
Chen
treatment of moderate
DY, 2019
to severe rheumatoid
arthritis: a costeffectiveness
analysis compared with
adalimumab in Taiwan.

A trial where costeffectiveness and cost-utility
analyses from health and social
care perspectives were
considered. Open label
12month RCT. Costs were
linked with the Heath
Assessment Questionnaire
(HAQ; primary outcome) and
quality-adjusted life years
(QALYs).

Starting treatment with
cDMARDs, rather than
TNF is, achieves similar
outcomes at significantly
lower costs. Patients with
active rheumatoid
arthritis and meeting NICE
criteria for expensive
biologics can costeffectively be treated with
combinations of intensive
synthetic disease
modifying drugs. (Patel et
al., 2019)

Simulation model to project
lifetime costs and QALYs.
Basecase analysis compared
second-line treatment with
tofacitinib
plus MTX versus adalimumab

From a payer perspective,
second-line treatment with
tofacitinib plus MTX is
a cost-effective treatment
strategy, compared with
adalimumab plus MTX, in
patients with moderate to
severe RA in Taiwan.
(Chen et al., 2019)

MTX. Efficacy was measured
by change in HAQ-DI score.
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5.

Materials used

5.1

Study design: Retrospective observational study

5.2

Study site: The study was conducted in the Medical Records and Finance departments at

Kasturba Hospital, Manipal
5.3

Study period: 12 months (10th August 2018 to 9th August 2019)

5.4

Departments involved: Department of Pharmacy Practice, MCOPS, Manipal and

Department of Medicine, KMC, Manipal.
5.5

Ethical clearance: The study was approved by Institutional Ethics Committee (IEC)

Kasturba Hospital, Manipal. IEC no-421/2018 (Appendix I)
5.6

Study criteria

5.6.1

Inclusion criteria: In Patients records of patients with Rheumatoid Arthritis admitted in

medicine unit (January 2016 - December 2018) were included.
5.6.2

Exclusion criteria: Medico-legal cases and missing data.

5.7

Sample size: A total of 322 records were collected and analyzed as these fulfilled the

required parameters.
5.8

Methodology

Review of literature for similar studies was conducted to get an insight to create and design the
study focusing on methodology and planning. Individual case record form for patients were
designed to capture data such as demographic, social habit, laboratory investigations,
medications prescribed as well as all the direct medical cost.
Protocol for the study design was prepared and submitted to the institutional ethics committee for
approval. Data collection was carried out from the in-patient files from Medicine unit with ICD
code M06.9 in the medical records department. All data was categorized and entered into SPSS
and analysis was done.
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5.9

Pharmaco-economic evaluation

Pharmaco-economic evaluation was conducted where the direct costs involved in the therapy
was collected. Data was collected from the finance department by accessing the inpatient bills,
which included all the charges involved by the patient during the period of hospitalization.
Cost data for patients admitted which was categorized under the following sub-costs:
admission charges, anesthesia charges, bed charges, central sterile supply, consultation charges,
vegetarian diet charges, CT scan charges, general store charges, investigation charges
(biochemistry, blood bank, clinical laboratory, ECG, microbiology, pathology and radiology),
materials, medicine charges, MRI, nursing charges, operation charges, oxygen, physiotherapy,
cardiac procedure, radiology procedures, other procedures, professional charges, subconsultation and miscellaneous costs. The total cost was calculated for each patient which were
either paid by the patient or by the Insurance Company or under the AROGYA system of the
hospital.
5.10

Statistical methods

Various statistical analysis and comparison tables and graphs were designed to understand the
demographic details, prescription pattern and cost distribution among the sample patient
population. The above tests were done by SPSS version 20.0.
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Design plan of study (Protocol)

Ethical Approval Process

Data Collection

Data Entry

Data Analysis and Interpretation

Report/Thesis Writing

Figure 1: Study Flow Chart
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6.

Results and Discussion

6.1

Demographic characters of Patients

Out of 322 Rheumatoid Arthritis patients in the gender distribution was 80% females (257) and
20% males (65). This study shows a predominance of RA in females with 80% being females.
The mean age was found to be 53 ± 12.3 years (Range 17-94). These results coincided with
another South Indian study on RA where the percentage of females was 82.5 % and those of
males were 17.5%. Their mean age group was found to be 52.6 ± 10.89 (Alex et al., 2015)
The average weight of the patients in our study was found to be 56.5 ± 14.10 kg, the average
height was at 150.7 ± 10.36 cm and the average BMI of the patients was at 25.3 ± 6.23 kg/m2.
Obesity is linked to a modest risk of developing RA. However, all the patients in the sample are
just within the normal BMI range. The average Length of Stay for patients was found to be 6 ±
5.09 days. The patients average ESR was 59.6 ± 29.93 mm/hr and average hemoglobin was 11.3
± 5.9 g/dl.
Table 2: Demography of Patients
Parameters

Mean ± SD

Age

53 ± 12.3 years

Weight

56.5 ± 14.10 kg

Height

150.7 ± 10.36 cm

BMI

25.3 ± 6.23 kg/m2

Length of Stay

06 ± 5.09 days

ESR

59.6 ± 29.93 mm/hr

Hb

11.3 ± 5.9 g/dl
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Figure 2: Gender Distribution of Patients

Figure 3: Age Distribution of RA Patients
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6.2

Duration of Disease and Length of Stay

The pharmacoeconomic burden of the disease is greatly impacted by the duration of disease
(severity condition) and the length of stay for the patient in the hospital contributing to the total
cost of illness of the RA patient. Our study revealed that 59 patients were newly diagnosed and
in 23 of the patient file records duration of disease was not mentioned. 100 patients were just
within the first year of their diagnosis. 60% of the patients had RA for less than 10 years.
The average length of stay for patient in the hospital was 6 days with the minimum of a single
day admission and maximum of 18 days.

Figure 4: Duration of Disease vs Number of Patients
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6.3

Cost of Illness for Rheumatoid Arthritis patients

All the costs for the in-patient charges for the Rheumatoid Arthritis patients were for a single
admission. The median, maximum and minimum cost for various categories of services are listed
in the table below. The total median cost for single admission was found to be INR 12,247
whereas the maximum reached INR 2,00,000 and the minimum was INR 2,000 as of 2018.

Figure 5: The Median Costs for RA Patients (INR)
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Table 2: In-Patients Cost Breakdown for RA Patients (INR)
Title
Admission charges
Anaesthesia charges
Bed charges
Blood bank
Central sterile supply
Consultation charges
CT scan
Diet veg
ECG
General store
Investigation Biochemistry
Investigation Clinical lab
Investigation Microbiology
Investigation Pathology
Investigation Radiology
Materials
Medicine charges
MRI
Nursing charges
Operation charges total
Oxygen
Physiotherapy
Procedure cardiac
Procedure radiology
Procedure others
Professional charges
Sub consultation
Miscellaneous
Total
Arogya
Insurance

Median
110
2431
600
302
180
130
5860
300
100
374
2040
470
1925
400
160
437
1496
5000
960
0
2370
240
1000
600
750
450
200
16
12247
2754
11808

Maximum
500
15242
35000
775
990
1200
9570
900
825
11304
21670
10470
14460
760
3580
9889
87463
8910
13900
40926
9400
2040
4200
4290
8810
12000
1500
123021
225578
23324
86803

Minimum
100
750
90
126
10
35
225
2
75
13
70
80
18
100
150
10
27
1236
160
0
90
60
50
100
20
70
100
1708
2037
1008
517

The investigation cost was highest for biochemistry coming to a median value of INR 2040 per
patient, followed by microbiology investigation cost at INR 1925. Radiological investigations
including X-Ray, CT scan, MRI, Ultrasound cost the patients a median of INR 600 but those
patients with CT scan or MRI would incur an additional median INR 5000. The study found that
29

69.2% of the patients were asked to perform at least one X-Ray test whereas 90% of the patients
suffering from RA were asked to do at least one of the Radiological investigations (CT, MRI,
Ultrasound or X-Ray).
Table 3: Radiological Investigations and X-Ray

6.4

Yes

No

X Ray

223

99

Radiological Investigation

290
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Medication Status of Patients

The medication status of the patients in the sample showed that while 54.3% (175) of the patients
claimed that they were regularly on RA medication, 27.3% (88) of the patients had recently been
as not mentioned and 3% (13) had
stopped medication, a few being irregular (9) and 3% (10) taking ayurvedic medication. This
analysis has limitation as many patients may not reveal taking ayurvedic medication or admit to
being non-adherent on their regular RA medication and as the study design is retrospective, only
the data recorded in the patient file is taken as the final account on the matter.

Figure 6: Medication Status of Patients
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6.5

Comorbid Disease Status

The patients suffering from Rheumatoid Arthritis were found to have other comorbid conditions
such as Type II diabetes mellitus (T2DM), hypertension (HTN), thyroid disorder, anemia,
infections, cardiovascular diseases as well as renal disorders. The most three of the highest
occurring co-morbid conditions seen among RA patients were T2DM, HTN and thyroid
disorders. 40% of the patients were suffering from HTN, 30% from T2DM and 16% had Thyroid
disorder. The comorbid conditions not only worsen the patient condition but also increase the
medication cost burden on the patients suffering from RA.
Table 4: Comorbid Diseases in RA Patients
Disease

6.6

Yes

No

T2DM

97

225

HTN

130

192

Thyroid Disorders

54

268

Prescription Pattern for RA Patients

The prescription pattern for RA patients revealed that DMARDs were prescribed as first line of
treatment for patients. The DMARDs prescribed included methotrexate, hydroxychloroquine,
leflunomide and sulfasalazine. There were 18% of patients who were not on any DMARDs while
22% of patients were on a single DMARD. The most commonly prescribed DMARDs was
methotrexate prescribed for 202 patients (62%) followed closely by hydroxychloroquine
prescribed to 194 patients (59.6%). They were also the most commonly prescribed drugs as a
combination therapy at 45.9%.
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Table 5: DMARDs Prescription Pattern in RA Patients
Number of Patients

DMARDs prescription

60 (18%)

0

72 (22%)

1 (Single DMARD)

152 (47.2%)

2 (Combination of Two DMARDs)

37 (11.4%)

3 (Combination of Three DMARDs)

1 (0.3%)

4 (Combination of Four DMARDs)

These results were similar to another study done which revealed that 33% of the patients were on
combination of three DMARDs and the most commonly (Alex et al., 2015).As well the most
commonly prescribed combination of two DMARDs being the same: methotrexate and
hydroxychloroquine given to 67% of patients which is higher than our findings of 47.2%
(Gawde, 2013)
6.7

Dose Distribution for DMARDs

Among the DMARDs prescribed, the most prescribed dose for hydroxychloroquine was 400 mg
(75%), for methotrexate it was 7.5mg (64.3%), for leflunomide it was 10mg (71.4%) and for
sulphasalazine it was 1g (62.5%) as seen in the graphs below. 194 (60.2%) patients were on
HCQ, 202 (62.2%) patients were on methotrexate whereas only 28 (8%) on leflunomide and 48
(14.9%) on sulphasalazine.

Figure 7: Dose of HCQs
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Figure 7b: Dose of Methotrexate

Figure 7c: Dose of Leflunomide

33

Figure 7d: Dose of Sulphasalazine

Table 6: Steroid Prescription in RA Patients
S No

Steroid Prescription in RA Patients

1.

No

149 (46.3%)

2.

Yes

173 (53.7%)

Name of Steroid

Frequency

1.

Prednisolone

147 (84.9%)

2.

Methylprednisolone

21 (12.1%)

3.

Hydrocortisone

4 (2.3%)

4.

Total

173

Dosage Form

Frequency

1.

Tablet

140 (80.9%)

2.

Injection

17 (9.8%)

3.

Tablet and Injection

15 (4.6%)
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The prescription for RA patients which included steroids were 53.7% (173). The steroid that was
most commonly prescribed was prednisolone 84.9 % (147), followed by methylprednisolone
12.1% (21) and hydrocortisone 2.3% (4). The dosage form of steroids that was most commonly
prescribed was tablet 80.9% (140) followed by injections 9.8% (17) and a combination of both
was given to 4.6% (15) as given in the table above. The steroid prescribing pattern in this study
was higher compared to other similar studies where 22% of the patients where on a steroid
(prednisolone, same as our study) (Gawde, 2013) and another study where the 37% of RA
patients had a steroid prescription. The steroid prescribing pattern may vary as per the disease
severity of the patient pool sample in the study.
Another commonly prescribed medication for RA patients is non-steroidal anti-inflammatory
drugs. According to a similar study 87%of the patients were prescribed with NSAIDs (Gawde,
2013). Our study found that NSAIDs was prescribed to 45% of the patients, most commonly
naproxen (64 patients) and followed by aceclofenac and diclofenac whereas tramadol and painrelieving gels were prescribed to 10% (33 patients).
Other commonly prescribed medications for RA patients were folic acid (62.5%) and calcium
supplements (37.2%) along with other medication to treat and manage comorbidities which
contribute to the median cost value on medication of INR 1496.
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CONCLUSION
7. Conclusion
In this study emphasis was mainly on the cost of illness and the prescription pattern of
Rheumatoid Arthritis patients admitted in the hospital. The total median cost for single
admission was found to be INR 12, 247. This is a very high amount in a developing country such
as India. This cost may be higher in our study as compared to other study as the study sample is
from a private tertiary hospital. Medicine cost of INR1496 is a significant contributor to RA cost
of illness.
The prescription pattern of medication for RA was found to be comparable and followed the
treatment guidelines however there is a scope for reducing medication burden and polypharmacy
thus assisting patients to ensure better adherence and decrease cost.
Our study found that 59 patients were newly diagnosed, and 100 patients were just within the
first year of their diagnosis which is the peak time to start effective treatment regimen, disease
education and awareness to ensure that disease progression can be prevented by reinforcing the
importance of medication adherence among patients. This is a white space role that can be taken
up by health care professionals.
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LIMITATIONS
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LIMITATIONS OF THE STUDY
8.

Limitations
The total financial burden of RA could not be quantified as indirect cost of therapy and
direct non-medical cost has not been considered for analysis as this study does not
involve patient interaction due to retrospective study design.
Severity of RA has not been described in the study as the diagnostic parameters and tests
were missing in patient files and were not uniform across all patients considered for the
study sample.

Cost could not be classified based on severity due to every patient being assigned
different diagnostic tests hence lacking common ground to assess severity of sample
population.
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FUTURE
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FUTURE CONSIDERATIONS
9.

Future considerations
Further prospective studies with larger sample size will shed greater insight into the exact
cost burden for RA as the severity of disease based on diagnostic tests and full cost
analysis (indirect) can be included. This is the need of the hour especially in India as the
Indian healthcare setting is slowly embracing insurance schemes. The impact of this on
cost of illness of RA can be studied in order to evaluate the best cost-effective treatments
for RA patients while ensuring adherence to decrease disease burden.
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